Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: A model-based analysis

Science Translational Medicine

Volumn 5, Issue 180, 2013, Pages

  Mills, Harriet L ^a   Cohen, Ted ^b,c   Colijn, Caroline ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CHEMOPROPHYLAXIS; DRUG RESISTANT TUBERCULOSIS; INTERSPECIFIC COMPETITION; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84877765955     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005260     Document Type: Article

References (48)

1. P. Romano, A. Manniello, O. Aresu, M. Armento, M. Cesaro, B. Parodi, Cell Line Data Base: Structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res. 37, D925-D932 (2009).
2. World Health Organization, Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings; http://www. who.int/hiv/pub/tb/9789241500708/en/ index.html.
3. E. L. Corbett, C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, C. Dye, The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021 (2003).
4. C. Akolo, I. Adetifa, S. Shepperd, J. Volmink, Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 1, CD000171 (2010).
5. World Health Organization, Global Tuberculosis Control Report 2011; http://www.who.int/ tb/publications/global-report/en/ [accessed April 2012].
6. W. Lew, M. Pai, O. Oxlade, D. Martin, D. Menzies, Initial drug resistance and tuberculosis treatment outcomes: Systematic review and meta-analysis. Ann. Intern. Med. 149, 123-134 (2008).
7. D. Menzies, A. Benedetti, A. Paydar, S. Royce, P. Madhukar, W. Burman, A. Vernon, C. Lienhardt, Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: A systematic review and meta-analysis. PLoS Med. 6, e1000150 (2009).
8. M. E. Balcells, S. L. Thomas, P. Godfrey-Faussett, A. D. Grant, Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 12, 744-751 (2006).
9. J. H. Day, S. Charalambous, K. L. Fielding, R. J. Hayes, G. J. Churchyard, A. D. Grant, Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int. J. Tuberc. Lung Dis. 10, 523-529 (2006).
10. I. V. Bassett, B. Wang, S. Chetty, J. Giddy, E. Losina, M. Mazibuko, B. Bearnot, J. Allen, R. P. Walensky, K. A. Freedberg, Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin. Infect. Dis. 51, 823-829 (2010).
11. G. J. Churchyard, K. L. Fielding, J. J. Lewis, V. N. Chihota, Y. Hanifa, A. D. Grant, Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: Yield and proportion missed at screening. AIDS 24 (Suppl. 5), S19-S27 (2010).
12. T. Kufa, V.Mngomezulu, S. Charalambous, Y. Hanifa, K. Fielding, A. D. Grant, N.Wada, R. E. Chaisson, G. J. Churchyard, C. R. Gounder, Undiagnosed tuberculosis among HIV clinic attendees: Association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J. Acquir. Immune Defic. Syndr. 60, e22-e28 (2012).
13. W. P. Gill, N. S. Harik, M. R. Whiddon, R. P. Liao, J. E. Mittler, D. R. Sherman, A replication clock for Mycobacterium tuberculosis. Nat. Med. 15, 211-214 (2009).
14. C. B. Ford, P. L. Lin, M. R. Chase, R. R. Shah, O. Iartchouk, J.Galagan, N. Mohaideen, T. R. Ioerger, J. C. Sacchettini, M. Lipsitch, J. L. Flynn, S. M. Fortune, Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482-486 (2011).
15. I. Sutherland, E. Svandova, S. Radhakrishna, The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63, 255-268 (1982).
16. E. Vynnycky, P. E. Fine, The natural history of tuberculosis: The implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183-201 (1997).
17. E. Brooks-Pollock, M. C. Becerra, E. Goldstein, T. Cohen, M. B. Murray, Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru. J. Infect. Dis. 203, 1582-1589 (2011).
18. J. R. Andrews, F. Noubary, R. P. Walensky, R. Cerda, E. Losina, C. R. Horsburgh, Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54, 784-791 (2012).
19. T. Cohen, M. Lipsitch, R. P. Walensky, M. Murray, Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc. Natl. Acad. Sci. U.S.A. 103, 7042-7047 (2006).
20. P. D. Ghys, T. Brown, N. C. Grassly, G. Garnett, K. A. Stanecki, J. Stover, N. Walker, The UNAIDS Estimation and Projection Package: A software package to estimate and project national HIV epidemics. Sex. Transm. Infect. 80 (Suppl. 1), i5-i9 (2004).
21. H. L. David, Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20, 810-814 (1970).
22. J. M. Tufariello, J. Chan, J. L. Flynn, Latent tuberculosis: Mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 3, 578-590 (2003).
23. C. E. Barry III, H. I. Boshoff, V. Dartois, T. Dick, S. Ehrt, J. Flynn, D. Schnappinger, R. J. Wilkinson, D. Young, The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855 (2009).
24. H. Getahun, W. Kittikraisak, C. M. Heilig, E. L. Corbett, H. Ayles, K. P. Cain, A. D. Grant, G. J. Churchyard, M. Kimerling, S. Shah, S. D. Lawn, R. Wood, G. Maartens, R. Granich, A. A. Date, J. K. Varma, Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. PLoS Med. 8, e1000391 (2011).
25. N. Aït-Khaled, E. Alarcon, K. Bissell, F. Boillot, J. A. Caminero, C. Y. Chiang, P. Clevenbergh, R. Dlodlo, D. A. Enarson, P. Enarson, O. Ferroussier, P. I. Fujiwara, A. D. Harries, E. Heldal, S. G. Hinderaker, S. J. Kim, C. Lienhardt, H. L. Rieder, I. D. Rusen, A. Trébucq, A. Van Deun, N. Wilson, Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues. Int. J. Tuberc. Lung Dis. 13, 927-935 (2009).
26. C. L. van Halsema, K. L. Fielding, V. N. Chihota, E. C. Russell, J. J. Lewis, G. J. Churchyard, A. D. Grant, Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 24, 1051-1055 (2010).
27. H. E. Jenkins, M. Zignol, T. Cohen, Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 6, e22927 (2011).
28. M. Richardson, N. M. Carroll, E. Engelke, G. D. Van Der Spuy, F. Salker, Z. Munch, R. P. Gie, R. M. Warren, N. Beyers, P. D. Van Helden, Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-incidence community setting. J. Clin. Microbiol. 40, 2750-2754 (2002).
29. R. M. Warren, T. C. Victor, E. M. Streicher, M. Richardson, N. Beyers, N. C. Gey van Pittius, P. D. van Helden, Patients with active tuberculosis often have different strains in the same sputum specimen. Am. J. Respir. Crit. Care Med. 169, 610-614 (2004).
30. D. García de Viedma, M. Marín, M. J. Ruiz, E. Bouza, Analysis of clonal composition of Mycobacterium tuberculosis isolates in primary infections in children. J. Clin. Microbiol. 42, 3415-3418 (2004).
31. I. C. Shamputa, L. Rigouts, L. A. Eyongeta, N. A. El Aila, A. van Deun, A. H. Salim, E. Willery, C. Locht, P. Supply, F. Portaels, Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J. Clin. Microbiol. 42, 5528-5536 (2004).
32. T. Cohen, P. D. van Helden, D. Wilson, C. Colijn, M. M. McLaughlin, I. Abubakar, R. M. Warren, Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin. Microbiol. Rev. 25, 708-719 (2012).
33. D. G. du Plessis, R. Warren, M. Richardson, J. J. Joubert, P. D. van Helden, Demonstration of reinfection and reactivation in HIV-negative autopsied cases of secondary tuberculosis: Multilesional genotyping of Mycobacterium tuberculosis utilizing IS 6110 and other repetitive element-based DNA fingerprinting. Tuberculosis 81, 211-220 (2001).
34. C. L. Cosma, O. Humbert, L. Ramakrishnan, Superinfecting mycobacteria home to established tuberculous granulomas. Nat. Immunol. 5, 828-835 (2004).
35. C. L. Cosma, O. Humbert, D. R. Sherman, L. Ramakrishnan, Trafficking of superinfecting Mycobacterium organisms into established granulomas occurs in mammals and is independent of the Erp and ESX-1 mycobacterial virulence loci. J. Infect. Dis. 198, 1851-1855 (2008).
36. R. Sergeev, C. Colijn, T. Cohen, Models to understand the population-level impact of mixed strain M. tuberculosis infections. J. Theor. Biol. 280, 88-100 (2011).
37. M. Henao-Tamayo, A. Obregón-Henao, D. J. Ordway, S. Shang, C. G. Duncan, I. M. Orme, A mouse model of tuberculosis reinfection. Tuberculosis 92, 211-217 (2012).
38. A. R. Wargo, S. Huijben, J. C. de Roode, J. Shepherd, A. F. Read, Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. U.S.A. 104, 19914-19919 (2007).
39. W. E. Harrington, T. K. Mutabingwa, A. Muehlenbachs, B. Sorensen, M. C. Bolla, M. Fried, P. E. Duffy, Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U.S.A. 106, 9027-9032 (2009).
40. S. Basu, D. Maru, E. Poolman, A. Galvani, Primary and secondary tuberculosis preventive treatment in HIV clinics: Simulating alternative strategies. Int. J. Tuberc. Lung Dis. 13, 652-658 (2009).
41. J. Cohen, Infectious disease. Approval of novel TB drug celebrated - With restraint. Science 339, 130 (2013).
42. G. J. Churchyard, G. Friedland, K. Fielding, E. Nardell, Opportunities afforded by new drugs for tuberculosis. Lancet Infect. Dis. 10, 368-369 (2010).
43. S. M. Blower, H. Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int. Stat. Rev. 62, 229-243 (1994).
44. S. M. Blower, A. R. McLean, T. C. Porco, P. M. Small, P. C. Hopewell, M. A. Sanchez, A. R. Moss, The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1, 815-821 (1995).
45. C. Dye, M. A. Espinal, Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268, 45-52 (2001).
46. T. Samandari, T. B. Agizew, S. Nyirenda, Z. Tedla, T. Sibanda, N. Shang, B. Mosimaneotsile, O. I. Motsamai, L. Bozeman, M. K. Davis, E. A. Talbot, T. L. Moeti, H. J. Moffat, P. H. Kilmarx, K. G. Castro, C. D. Wells, 6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebocontrolled trial. Lancet 377, 1588-1598 (2011).
47. V. H. Springett, Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle 52, 73-87 (1971).
48. G. Hughes, C. Currie, E. Corbett. Modeling tuberculosis in areas of high HIV prevalence, Simulation Conference, 2006. WSC 06. Proceedings of the Winter (IEEE, Washington, DC, 2006), pp. 459-465.